# BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 YTD Q2 P&L / Income Statement

- Company: BIOCRYST PHARMACEUTICALS, INC. (BCRX)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001628280-26-053300
- Page: https://plicit.ai/financials/bcrx/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/bcrx-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 374,663,000 US dollars
- **Cost of product sales**: 9,217,000 US dollars
- **Gross profit (calculated)**: 365,446,000 US dollars
- **Operating expenses (calculated)**: 968,579,000 US dollars
- **Income (loss) from operations**: negative 603,133,000 US dollars
- **Total other expense, net**: negative 38,201,000 US dollars
- **Income (loss) before income taxes**: negative 641,334,000 US dollars
- **Income tax expense**: 2,083,000 US dollars
- **Net income (loss)**: negative 643,417,000 US dollars
- **Product sales, net**: 308,914,000 US dollars
- **License and other revenues**: 65,749,000 US dollars
- **Acquired in-process research and development**: 697,761,000 US dollars
- **Research and development**: 112,288,000 US dollars
- **Selling, general and administrative**: 158,530,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Arrangement

- Page: https://plicit.ai/financials/bcrx/fy2026-ytd-q2-income-statement/revenue-by-arrangement
- Chart image: https://plicit.ai/charts/bcrx-fy2026-ytd-q2-revenue-by-arrangement-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 374,663,000 US dollars
- **Cost of product sales**: 9,217,000 US dollars
- **Gross profit (calculated)**: 365,446,000 US dollars
- **Operating expenses (calculated)**: 968,579,000 US dollars
- **Income (loss) from operations**: negative 603,133,000 US dollars
- **Total other expense, net**: negative 38,201,000 US dollars
- **Income (loss) before income taxes**: negative 641,334,000 US dollars
- **Income tax expense**: 2,083,000 US dollars
- **Net income (loss)**: negative 643,417,000 US dollars
- **Kaken License Agreement**: 2,454,000 US dollars
- **Neopharmed**: 55,729,000 US dollars
- **Undisclosed (calculated)**: 316,480,000 US dollars
- **Acquired in-process research and development**: 697,761,000 US dollars
- **Research and development**: 112,288,000 US dollars
- **Selling, general and administrative**: 158,530,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service by Arrangement

- Page: https://plicit.ai/financials/bcrx/fy2026-ytd-q2-income-statement/revenue-by-product-and-service-by-arrangement
- Chart image: https://plicit.ai/charts/bcrx-fy2026-ytd-q2-revenue-by-product-and-service-by-arrangement-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 374,663,000 US dollars
- **Cost of product sales**: 9,217,000 US dollars
- **Gross profit (calculated)**: 365,446,000 US dollars
- **Operating expenses (calculated)**: 968,579,000 US dollars
- **Income (loss) from operations**: negative 603,133,000 US dollars
- **Total other expense, net**: negative 38,201,000 US dollars
- **Income (loss) before income taxes**: negative 641,334,000 US dollars
- **Income tax expense**: 2,083,000 US dollars
- **Net income (loss)**: negative 643,417,000 US dollars
- **License and other revenues - Neopharmed**: 54,513,000 US dollars
- **Research and Development - Neopharmed**: 1,216,000 US dollars
- **Undisclosed (calculated)**: 318,934,000 US dollars
- **Acquired in-process research and development**: 697,761,000 US dollars
- **Research and development**: 112,288,000 US dollars
- **Selling, general and administrative**: 158,530,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (2)

- Page: https://plicit.ai/financials/bcrx/fy2026-ytd-q2-income-statement/revenue-by-product-and-service-2
- Chart image: https://plicit.ai/charts/bcrx-fy2026-ytd-q2-revenue-by-product-and-service-2-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Product and service (Schedule of Revenues). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 374,663,000 US dollars
- **Cost of product sales**: 9,217,000 US dollars
- **Gross profit (calculated)**: 365,446,000 US dollars
- **Operating expenses (calculated)**: 968,579,000 US dollars
- **Income (loss) from operations**: negative 603,133,000 US dollars
- **Total other expense, net**: negative 38,201,000 US dollars
- **Income (loss) before income taxes**: negative 641,334,000 US dollars
- **Income tax expense**: 2,083,000 US dollars
- **Net income (loss)**: negative 643,417,000 US dollars
- **ORLADEYO**: 306,549,000 US dollars
- **License and other revenues**: 68,114,000 US dollars
- **Acquired in-process research and development**: 697,761,000 US dollars
- **Research and development**: 112,288,000 US dollars
- **Selling, general and administrative**: 158,530,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.